http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 04 Jun 2026 06:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Pulmatrix%2C+Inc.++++++++++++++++++++++/26601988.html si-local-file:///var/storage/secattach/20260604/26601988.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Pulmatrix%2C+Inc.++++++++++++++++++++++/26601988.html Thu, 04 Jun 2026 06:11:00 -0400 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Pulmatrix%2C+Inc.++++++++++++++++++++++/26601988.html si-local-file:///var/storage/secattach/20260604/26601988.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Pulmatrix%2C+Inc.++++++++++++++++++++++/26601988.html Thu, 04 Jun 2026 06:11:00 -0400 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+May+15/26499970.html si-local-file:///var/storage/secattach/20260515/26499970.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+May+15/26499970.html Fri, 15 May 2026 08:21:00 -0400 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+May+15/26499970.html si-local-file:///var/storage/secattach/20260515/26499970.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+May+15/26499970.html Fri, 15 May 2026 08:21:00 -0400 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Mar+31/26499972.html si-local-file:///var/storage/secattach/20260515/26499972.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Mar+31/26499972.html Fri, 15 May 2026 08:21:00 -0400 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Mar+31/26499972.html si-local-file:///var/storage/secattach/20260515/26499972.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Mar+31/26499972.html Fri, 15 May 2026 08:21:00 -0400 O.16904700 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html <div class="xn-content"> <p class="prntac"><i>Announced merger agreement with Eos SENOLYTIX in March</i></p><p class="prntac"><i>Closed private placement of preferred stock</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4689549-1&amp;h=3881631193&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html Fri, 15 May 2026 08:20:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html <div class="xn-content"> <p class="prntac"><i>Announced merger agreement with Eos SENOLYTIX in March</i></p><p class="prntac"><i>Closed private placement of preferred stock</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4689549-1&amp;h=3881631193&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html Fri, 15 May 2026 08:20:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html <div class="xn-content"> <p class="prntac"><i>Announced merger agreement with Eos SENOLYTIX in March</i></p><p class="prntac"><i>Closed private placement of preferred stock</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4689549-1&amp;h=3881631193&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html Fri, 15 May 2026 08:20:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html <div class="xn-content"> <p class="prntac"><i>Announced merger agreement with Eos SENOLYTIX in March</i></p><p class="prntac"><i>Closed private placement of preferred stock</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4689549-1&amp;h=3881631193&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html Fri, 15 May 2026 08:20:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html <div class="xn-content"> <p class="prntac"><i>Announced merger agreement with Eos SENOLYTIX in March</i></p><p class="prntac"><i>Closed private placement of preferred stock</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4689549-1&amp;h=3881631193&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html Fri, 15 May 2026 08:20:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html <div class="xn-content"> <p class="prntac"><i>Announced merger agreement with Eos SENOLYTIX in March</i></p><p class="prntac"><i>Closed private placement of preferred stock</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4689549-1&amp;h=3881631193&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html Fri, 15 May 2026 08:20:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html <div class="xn-content"> <p class="prntac"><i>Announced merger agreement with Eos SENOLYTIX in March</i></p><p class="prntac"><i>Closed private placement of preferred stock</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4689549-1&amp;h=3881631193&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html Fri, 15 May 2026 08:20:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html <div class="xn-content"> <p class="prntac"><i>Announced merger agreement with Eos SENOLYTIX in March</i></p><p class="prntac"><i>Closed private placement of preferred stock</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4689549-1&amp;h=3881631193&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+First+Quarter+2026+Financial+Results/26499964.html Fri, 15 May 2026 08:20:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Pulmatrix%2C+Inc.++++++++++++++++++++++++Filed+by%3A+RCM+Eos+PIPE+HOLDINGS%2C+LLC/26351828.html si-local-file:///var/storage/secattach/20260422/26351828.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Pulmatrix%2C+Inc.++++++++++++++++++++++++Filed+by%3A+RCM+Eos+PIPE+HOLDINGS%2C+LLC/26351828.html Wed, 22 Apr 2026 16:24:00 -0400 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Pulmatrix%2C+Inc.++++++++++++++++++++++++Filed+by%3A+RCM+Eos+PIPE+HOLDINGS%2C+LLC/26351828.html si-local-file:///var/storage/secattach/20260422/26351828.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Pulmatrix%2C+Inc.++++++++++++++++++++++++Filed+by%3A+RCM+Eos+PIPE+HOLDINGS%2C+LLC/26351828.html Wed, 22 Apr 2026 16:24:00 -0400 O.16904700 PULM http://www.streetinsider.com/Corporate+News/Pulmatrix+closes+%241+million+preferred+stock+placement+ahead+of+merger/26340386.html <p>Pulmatrix Inc. (NASDAQ: PULM) completed a private placement of Series B Convertible Preferred Stock with an affiliate of Eos SENOLYTIX Inc., raising approximately $1 million in gross proceeds before expenses. The transaction represents part of the company's planned merger with Eos.</p><p>The Series B Preferred Stock converts into common stock at $2.20 per share and can be exercised starting 90 days after the initial issuance date. The conversion price is subject to standard adjustments for stock dividends, splits, and similar corporate actions.</p><p>Pulmatrix intends to use the net proceeds for working capital and general corporate purposes. The preferred stockholders will vote alongside http://www.streetinsider.com/Corporate+News/Pulmatrix+closes+%241+million+preferred+stock+placement+ahead+of+merger/26340386.html Tue, 21 Apr 2026 08:05:40 -0400 PULM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Apr+16/26340288.html si-local-file:///var/storage/secattach/20260421/26340288.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Apr+16/26340288.html Tue, 21 Apr 2026 08:01:00 -0400 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Apr+16/26340288.html si-local-file:///var/storage/secattach/20260421/26340288.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Apr+16/26340288.html Tue, 21 Apr 2026 08:01:00 -0400 O.16904700 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html <div class="xn-content"> <p class="prntac"><i>Series B Preferred Stock investment made in Pulmatrix with a conversion price of <money>$2.20</money> is a part of the ongoing merger process </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>April 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4669135-1&amp;h=3021272178&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of <span>Eos SENOLYTIX, Inc.</span> ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html Tue, 21 Apr 2026 08:00:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html <div class="xn-content"> <p class="prntac"><i>Series B Preferred Stock investment made in Pulmatrix with a conversion price of <money>$2.20</money> is a part of the ongoing merger process </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>April 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4669135-1&amp;h=3021272178&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of <span>Eos SENOLYTIX, Inc.</span> ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html Tue, 21 Apr 2026 08:00:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html <div class="xn-content"> <p class="prntac"><i>Series B Preferred Stock investment made in Pulmatrix with a conversion price of <money>$2.20</money> is a part of the ongoing merger process </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>April 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4669135-1&amp;h=3021272178&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of <span>Eos SENOLYTIX, Inc.</span> ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html Tue, 21 Apr 2026 08:00:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html <div class="xn-content"> <p class="prntac"><i>Series B Preferred Stock investment made in Pulmatrix with a conversion price of <money>$2.20</money> is a part of the ongoing merger process </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>April 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4669135-1&amp;h=3021272178&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of <span>Eos SENOLYTIX, Inc.</span> ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html Tue, 21 Apr 2026 08:00:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html <div class="xn-content"> <p class="prntac"><i>Series B Preferred Stock investment made in Pulmatrix with a conversion price of <money>$2.20</money> is a part of the ongoing merger process </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>April 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4669135-1&amp;h=3021272178&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of <span>Eos SENOLYTIX, Inc.</span> ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html Tue, 21 Apr 2026 08:00:00 -0400 A.50216777 O.16904700 O.54516537 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html <div class="xn-content"> <p class="prntac"><i>Series B Preferred Stock investment made in Pulmatrix with a conversion price of <money>$2.20</money> is a part of the ongoing merger process </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>April 21, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4669135-1&amp;h=3021272178&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of <span>Eos SENOLYTIX, Inc.</span> ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Closing+of+Preferred+Stock+Transaction+as+Part+of+Planned+Merger/26340161.html Tue, 21 Apr 2026 08:00:00 -0400 A.50216777 O.16904700 O.54516537 PULM